BriaCell Net Working Capital from 2010 to 2024

BCTXW Stock  USD 0.34  0.03  9.68%   
BriaCell Therapeutics Net Working Capital yearly trend continues to be fairly stable with very little volatility. Net Working Capital is likely to outpace its year average in 2024. During the period from 2010 to 2024, BriaCell Therapeutics Net Working Capital regression line of quarterly data had mean square error of 326.3 T and geometric mean of  2,621,951. View All Fundamentals
 
Net Working Capital  
First Reported
2010-12-31
Previous Quarter
-3.8 M
Current Value
-3.6 M
Quarterly Volatility
18.4 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check BriaCell Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BriaCell Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 18.4 K, Interest Expense of 0.0 or Other Operating Expenses of 35 M, as well as many indicators such as Price To Sales Ratio of 0.0, Days Sales Outstanding of 0.0 or Invested Capital of 622.1 K. BriaCell financial statements analysis is a perfect complement when working with BriaCell Therapeutics Valuation or Volatility modules.
  
Check out the analysis of BriaCell Therapeutics Correlation against competitors.

Latest BriaCell Therapeutics' Net Working Capital Growth Pattern

Below is the plot of the Net Working Capital of BriaCell Therapeutics Corp over the last few years. It is BriaCell Therapeutics' Net Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BriaCell Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Working Capital10 Years Trend
Slightly volatile
   Net Working Capital   
       Timeline  

BriaCell Net Working Capital Regression Statistics

Arithmetic Mean7,857,666
Geometric Mean2,621,951
Coefficient Of Variation234.50
Mean Deviation13,362,803
Median932,677
Standard Deviation18,426,455
Sample Variance339.5T
Range61.8M
R-Value0.33
Mean Square Error326.3T
R-Squared0.11
Significance0.23
Slope1,351,864
Total Sum of Squares4753.5T

BriaCell Net Working Capital History

2024-3.6 M
2023-3.8 M
202225.1 M
202141.4 M
202057.2 M
2019-4.5 M
2018-1.2 M

About BriaCell Therapeutics Financial Statements

BriaCell Therapeutics investors use historical fundamental indicators, such as BriaCell Therapeutics' Net Working Capital, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BriaCell Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Working Capital-3.8 M-3.6 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for BriaCell Stock Analysis

When running BriaCell Therapeutics' price analysis, check to measure BriaCell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BriaCell Therapeutics is operating at the current time. Most of BriaCell Therapeutics' value examination focuses on studying past and present price action to predict the probability of BriaCell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BriaCell Therapeutics' price. Additionally, you may evaluate how the addition of BriaCell Therapeutics to your portfolios can decrease your overall portfolio volatility.